(1) a first layer containing one or more drugs
with immediate or controlled release
formulation;
(2) a second layer containing one or more drugs
with slow release formulation and
(3) a third layer, which is characterized as
being a low-permeability barrier coating.
25. The drugs in the second layer may be the same as
or different than the drugs in the first layer.
26. One preferred embodiment is shown in Fig. 2,
where 4 is the immediate or controlled release layer (1), 5 is
the slow release layer (2) and 6 is the barrier-type layer (3):
27. From claim 6 of Conte (col. 18), it is apparent
that two drugs contemplated for using in the Conte system are
L-dopa and carbidopa.
B. Discussion
1. Prima facie obviousness
- 10 -
Page: Previous 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Next
Last modified: November 3, 2007